CDH1 and hepatocellular carcinoma: A study by Dong et al. [43] using the hepatocellular carcinoma (HCC) cell line demonstrated that meloxicam executed its anticancer effects by aiming at the Cox-2/MMP-2/E-cadherin, AKT, apoptotic, and autophagic pathways in Cox-2-dependent and Cox-2-independent pathways.